eGFRcys resulted in smallest change in CKD prevalence among Black adults compared with race-blended, race-removed equations<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, July 30, 2021 (HealthDay News) — The chronic kidney disease (CKD) Epidemiology Consortium estimated glomerular filtration rate cystatin C (eGFRcys), the only guideline-recommended equation that does not require race, results in the smallest changes to eGFR among Black patients, according to a research letter published online July 29 in the Journal of the American Society of Nephrology<\/em>.<\/p>\n James A. Diao, from Boston Children’s Hospital, and colleagues compared eGFR distributions for race-free eGFR equations and equations using serum creatinine and requiring race (eGFRcr and eGFRcr-cys [computed from creatinine and cystatin C, respectively]). The distributions of eGFR were compared using data from the National Health and Nutrition Examination Survey, for a sample of 4,434 nonpregnant adults from 1999 to 2002.<\/p>\n The researchers found that eGFRcys resulted in the smallest change in CKD prevalence among Black adults relative to eGFRcr-cys (0.7 percent) compared to race-blended or race-removed equations (1.4 to 4.5 percent). The smallest median change in eGFR in Black adults was seen with eGFRcys (\u00e2\u0088\u00920.8 mL\/min\/1.73 m2<\/sup>) compared with other race-free alternatives, which varied from 11.3 to 29.0 for race-blended and race-removed models, respectively. The smallest gap in CKD prevalence between Black and White\/other patients was seen with eGFRcys (3.7 percent) relative to other race-free equations (6.1 to 7.4 percent).<\/p>\n “Our findings indicate that race-free alternatives may vary considerably in effects on chronic kidney disease classification,” a coauthor said in a statement. “We hope these estimates will be useful to the many individuals and groups working to improve kidney function estimation without race.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n